Palindromic rheumatism
Recurrent self-limiting arthritis · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A pattern of recurrent, self-limiting attacks of joint and periarticular inflammation lasting hours to days with complete resolution between episodes and no erosive damage. A substantial proportion, especially antibody-positive patients, progress to rheumatoid arthritis.
Red flags
- Attacks becoming more frequent, prolonged or additive
- Persistent synovitis between attacks (evolving RA)
- Development of joint erosions
- Systemic features suggesting connective tissue disease
- Fever/monoarthritis raising concern for sepsis or crystals
Assessment
Differential diagnosis
- Early rheumatoid arthritis
- Crystal arthropathy (gout / CPPD)
- Reactive arthritis
- Psoriatic arthritis
- Systemic lupus erythematosus
- Whipple disease
Investigations
- RF and anti-CCP (positivity predicts progression to RA)
- CRP/ESR during and between attacks
- Serum urate and joint aspiration if crystal disease suspected
- Radiographs (characteristically non-erosive)
- ANA to screen for connective tissue disease
- Ultrasound of affected joints during attack if diagnosis unclear
Management
- Document the episodic pattern: acute attacks with symptom-free intervals and no persistent swelling
- Exclude crystal arthropathy and infection during an acute attack
- Check RF and anti-CCP to stratify risk of progression to RA
- Treat acute attacks with NSAIDs or short corticosteroid courses
- Start hydroxychloroquine to reduce attack frequency and possibly delay progression to RA
- Counsel antibody-positive patients about RA risk and arrange monitoring
- Escalate to RA treatment pathway if persistent synovitis or erosions develop
- Arrange rheumatology follow-up to detect evolution to definite RA
Drugs & doses
Naproxen — 500 mg PO BD during acute attacks (with gastroprotection)
Prednisolone — 15-20 mg PO OD short course for severe attacks
Hydroxychloroquine — 200-400 mg PO OD (max 5 mg/kg/day) to reduce attack frequency
Colchicine — 500 micrograms PO OD-BD if frequent attacks (alternative suppressive option)
Disposition
Outpatient rheumatology follow-up with antibody-based risk stratification; no admission required.
Complications & pitfalls
- Progression to rheumatoid arthritis
- Evolution to other connective tissue disease
- Chronic pain and functional limitation
- Misdiagnosis delaying DMARD therapy
Exam pearls
- Complete resolution between attacks and no erosions distinguishes it from established RA
- Anti-CCP and RF positivity markedly increase risk of progression to RA
- Hydroxychloroquine reduces attack frequency and may delay RA onset
- Peri-articular (not just articular) swelling is characteristic
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.